InMed Pharmaceuticals (INM) Proxy Filing summary

Executive summary

• Annual general meeting scheduled for December 18, 2024, to be held virtually to maximize shareholder participation and accessibility.

• Key items include presentation of audited financials, election of five directors, re-appointment of Marcum LLP as auditor, and other business.

• Notice-and-access provisions are used for proxy materials, reducing physical mailings and providing online access.

• As of October 21, 2024, there are 13,353,431 common shares outstanding, each with one vote per share.

Voting matters and shareholder proposals

• Shareholders will vote on the election of five directors and the re-appointment of Marcum LLP as auditor.

• Shareholder proposals for the 2025 AGM must be received by June 30, 2025, to be considered for inclusion.

• Majority voting policy in place for director elections; directors must tender resignation if not supported by a majority.

Board of directors and corporate governance

• Board consists of five members, four of whom are independent; roles of CEO and Chair are separated.

• Board committees include Audit, Compensation, and Governance and Nomination, all with independent members.

• Board diversity: 40% women, 60% men; diversity considered in nominations but no formal targets.

• Board and committees met regularly in fiscal 2024, with high attendance rates.

• Written codes of conduct, insider trading, and related party transaction policies are in place.